Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial

• Published in: Journal of bone and mineral research Vol. 23; no. 12; pp. 1923 - 1934
• Main Authors: Silverman, Stuart L, Christiansen, Claus, Genant, Harry K, Vukicevic, Slobodan, Zanchetta, José R, de Villiers, Tobie J, Constantine, Ginger D, Chines, Arkadi A
• Format: Journal Article
• Language: English
• Published: Washington, DC John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR) 01.12.2008
• Subjects: Aged; Aged, 80 and over; bazedoxifene; Bone and Bones - pathology; Bone Density; Female; fracture risk; Fractures, Bone - drug therapy; Humans; Indoles - therapeutic use; Lumbar Vertebrae - pathology; Middle Aged; osteoporosis; Osteoporosis - drug therapy; Placebos; Postmenopause; selective estrogen receptor modulator; Selective Estrogen Receptor Modulators - pharmacology; Time Factors; treatment; Treatment Outcome
• ISSN: 0884-0431; 1523-4681; 1523-4681
• DOI: 10.1359/jbmr.080710

In this 3‐yr, randomized, double‐blind, placebo‐ and active‐controlled study, healthy postmenopausal women with osteoporosis (55–85 yr of age) were treated with bazedoxifene 20 or 40 mg/d, raloxifene 60 mg/d, or placebo. The primary endpoint was incidence of new vertebral fractures after 36 mo; seco...